FerulanoO., MerolaL.: Indagine clinica sull'aztone di un nuovo analgesico nelle sindromi dolorose urologiche. Minerva anest., 35; 6–19 (1969).
2.
WilkeyJ. L. e coll.: Pentazocine for the relief of pain following urological procedures. J. Urol., 97; 550–551 (1967).
3.
AndersonE. C. e coll.: Use of the new analgesic Talwin in urology. J. Urol., 96; 584–585 (1966).
4.
BirkowitzB. A. e coll.: Relationship of Pentazocine plasma levels to pharmacological activity in man. Clin. Pharmacol. Ther., 10; 320–328 (1969).
5.
DuncanS. L. B. e coll.: Comparison of Pentazocine and pethidine in normal labor. Am. J. Obst. & Gynec., 105; 197–202 (1969).
6.
RogersK. J., ThorntonJ. A.: The interaction between monoamine oxidase inhibitors and narcotic analgesic in mice. Brit. J. Pharmac., 36; 470–480 (1969.)
7.
BerkowitzB. e coll.: Metabolism and excretion of Pentazocine in man. Clin. Pharmacol. Ther., 10; 681–689 (1969).
8.
Flavett MattsS. G. e coll.: Radioisotopic studies of the urinary excretion of Pentazocine as an aid to its pharmacotherapeutic application. Clin. Trials. J., 4; 842–845 (1967).
9.
BeckettA. H., TaylorJ. F.: Blood concentrations of pethidine and Pentazocine in mother and infant at time of birth. J. Pharm. Pharmac., 19; 50–52 (1967).
10.
PittmanK. A. e coll.: Metabolism in vitro and in vivo of Pentazocine. Biochem. Pharmacol., 18; 1673–1678 (1969).
11.
HarrisL. S.: Narcotic antagonist in the benzomorphan series. Respiratory, cardiovascular and behavioral effects in dogs. Naunyn-Schmiedebergs Arch. Exp. Path. u. Pharmak., 248; 426–436 (1964).
12.
EvansW. O., BergnerD. P.: A comparison of the analgesic potencies of morphine, Pentazocine, and a mixture of methamphetamine and Pentazocine in the rat. J. New Drugs, 4; 82–85 (1964).
13.
HarrisL. S., PiersonA. K.: Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther., 143; 141–148 (1964).
14.
PearlJ. e coll.: Prevention of writhing and other effects of narcotics and narcotic antagonists in mice. J. Pharmacol. Exp. Ther., 160; 217–230 (1968).
15.
BlumbergH. e coll.: Counterection of narcotic antagonist analgesics by the narcotic antagonist naloxone. Proc. Soc. Exp. Biol. Med., 123; 755–758 (1966).
16.
FraserH. F., RosenbergD. E.: Studies on the human addiction liability of 2-hydroxy-5,9-dimetyl -2-(3,3-dimethylallyl)-6,7-benzomorphan (WIN 20,228): a weak narcotic antagonist. J. Pharmac. Exp. Ther., 143; 149–156 (1969).
17.
CollierH. O. J., SchneiderC.: Profiles of activity in rodents of some narcotic and narcotic antagonist drug. Nature, 224; 610–612 (1969).
18.
StrawR. N., MitchellC. L.: The effects of morphine, pentobarbital, Pentazocine and nalorphine on bioelectrical potentials evoked in the brain stem of the cat by electrical stimulation of the tooth pulp. J. Pharmacol. Exp. Ther., 146; 7–15 (1969).
19.
TiengoM. e coll.: Prima sperimentazione in analgesia ostetrica con Pentazocina (Talwin). Minerva anest., 35; 20–24 (1969).
20.
PearlJ., HarrisL. S.: Inhibition of writhing by narcotic antagonists. J. Pharmacol. Exp. Ther., 154; 319–323 (1966).
21.
PaddockR. e coll.: Analgesic and side effects of Pentazocine and’ morphine in a large population of postoperative patients. Clin. Pharmacol. Ther., 10; 355–465 (1969).
22.
ForrestW. H. e coll.: Analgesic and other effects of the d- and 1-isomers of Pentazocine. Clin. Pharmacol. Ther., 10; 468–476 (1969).
23.
HinshawJ. R. e coll.: Pentazocine: a potent nonaddicting analgesic. Amer. J. Med. Sci., 257; 95/57–100/62 (1966).
